CompletedPHASE2, PHASE3NCT02040090

Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects

Studying Rabies

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Kamada, Ltd.
Principal Investigator
Mark Matson, M.D.
Prism Research Inc
Intervention
Active rabies vaccine (US-FDA approved)(drug)
Enrollment
118 target
Eligibility
18-75 years · All sexes
Timeline
20132014

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02040090 on ClinicalTrials.gov

Other trials for Rabies

Additional recruiting or active studies for the same condition.

See all trials for Rabies

← Back to all trials